An overview of the management of patients with R/R Waldenström’s macroglobulinemia

Ramón Garcia Sanz, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain, discusses the management of patients with relapsed/refractory (R/R) Waldenström’s macroglobulinemia (WM). These patients can be divided into two groups: those who relapse after chemoimmunotherapy and those who are resistant or who relapse after BTK inhibitors (BTKis). For the former, a switch to BTKis, such as ibrutinib or acalabrutinib, is common. For the latter, BCL2-targeted agents such as venetoclax, non-covalent BTKis, chemotherapy, or CAR T-cells are all options. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.